share_log

Truist Securities Maintains Buy on Keros Therapeutics, Maintains $100 Price Target

Benzinga ·  Jun 18 13:48

Truist Securities analyst Srikripa Devarakonda maintains Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment